Q3 Financial Results 2024-25

RNS Number : 4581J

Beximco Pharmaceuticals PLC

24 June 2026

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS PLC.

Q3 Financial Results 2024-25

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients today announces its unaudited financial results for the third quarter and nine months ended 31 March 2025.

Financial Highlights (Consolidated)

Nine months ended 31 March 2025

· Net revenue increased 10.8% to Bangladesh Taka ("BDT") 36,622.0m / £235.0m (2023-24: BDT 33,050.9m / £239.1m)

o Domestic sales increased 8.5% to BDT 33,617.7m / £215.7m (2023-24: BDT 30,987.0m / £224.1m)

o Export sales increased 45.6% to BDT 3,004.3m / £19.3m (2023-24: BDT 2,063.9m / £14.9m)

· Profit after tax increased 20.3% to BDT 5,261.0m / £33.8m (2023-24: BDT 4,374.7m / £31.6m)

Third-quarter ended 31 March 2025

· Net revenue increased 14.8% to BDT 12,608.6m / £80.9m (2023-24: BDT 10,987.3m / £79.5m)

· Profit after tax increased 26.3% to BDT 1,726.0m / £11.1m (2023-24: BDT 1,366.6m / £9.9m)

The detailed accounts can be viewed at the Company website: www.beximcopharma.com

For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", released today.

(Exchange rates of £1=Taka 155.8649 for 31 March 2025 and £1=Taka 138.2585 for 31 March 2024 have been used in this announcement.)

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext. 20030

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: +880 2 41060531, Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy

Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of financial position (Un-audited)

As at March 31, 2025

	March 31, 2025	Taka '000 June 30, 2024
ASSETS

Non-current assets	49,405,558	48,526,439
Property, plant and equipment	43,383,769	42,487,711
Right-of-use assets	582,493	561,597
Intangible assets	4,691,106	4,720,697
Deferred tax asset	52,646	60,891
Goodwill	674,570	674,570
Other investments	20,974	20,973

Current assets	25,449,285	20,817,584
Inventories	14,100,238	12,118,129
Spares and supplies	844,783	896,665
Trade and other receivables	4,439,493	3,767,319
Loans, advances, deposits and prepayments	2,942,187	2,686,195
Advance income tax	339,484	295,170
Short term investment	900,000	200,000
Cash and cash equivalents	1,883,100	854,106

TOTAL ASSETS	74,854,843	69,344,023

SHAREHOLDERS' EQUITY AND LIABILITIES
Equity attributable to the owners of the company	51,398,004	47,949,965
Share capital	4,461,121	4,461,121
Share premium	5,269,475	5,269,475
Excess of issue price over face value of GDRs	1,689,637	1,689,637
Capital reserve on merger	294,951	294,951
Revaluation surplus	1,134,729	1,137,306
Unrealized gain/(loss)	18,149	18,148
Retained earnings	38,529,942	35,079,327

Non-controlling interest	3,948,520	3,952,938

TOTAL EQUITY	55,346,524	51,902,903

Non-current liabilities	8,389,072	7,879,133
Long term borrowings-net of current maturity	1,963,675	1,757,971
Liability for gratuity, pension and WPPF	3,863,051	3,546,580
Deferred tax liability	2,562,346	2,574,582

Current liabilities	11,119,247	9,561,987
Short term borrowings	4,386,777	2,996,660
Long term borrowings-current maturity	1,091,878	1,270,800
Trade and other payables	3,324,104	3,671,372
Accrued expenses	1,272,457	1,106,665
Dividend payable	311,718	87,223
Income tax payable	732,313	429,267
TOTAL LIABILITIES	19,508,319	17,441,120
TOTAL EQUITY AND LIABILITIES	74,854,843	69,344,023

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of profit or loss and other comprehensive income (Un-audited)

For the period July 2024-March 2025

				Taka '000

	July 2024 - March 2025	July 2023 - March 2024	January - March 2025	January - March 2024

Net revenue	36,621,960	33,050,916	12,608,553	10,987,338
Cost of goods sold	(19,822,775)	(18,448,115)	(6,787,928)	(6,184,085)

Gross profit	16,799,185	14,602,801	5,820,625	4,803,253

Operating expenses	(9,288,133)	(8,083,749)	(3,397,217)	(2,826,393)
General and administrative expenses	(1,026,632)	(985,625)	(338,255)	(333,191)
Selling, marketing and distribution expenses	(8,261,501)	(7,098,124)	(3,058,962)	(2,493,202)
Profit from operations	7,511,052	6,519,052	2,423,408	1,976,860

Other income	481,900	246,324	255,345	114,876
Finance cost	(802,608)	(860,732)	(314,630)	(289,030)
Profit before tax and WPPF	7,190,344	5,904,644	2,364,123	1,802,706
Contribution to WPPF	(351,606)	(286,781)	(116,347)	(86,901)
Profit before tax	6,838,738	5,617,863	2,247,776	1,715,805
Income tax expenses	(1,577,731)	(1,243,136)	(521,780)	(349,247)
Current tax	(1,580,974)	(1,293,986)	(517,572)	(369,934)
Deferred tax	3,243	50,850	(4,208)	20,687
Profit after tax	5,261,007	4,374,727	1,725,996	1,366,558

Profit/(loss) attributable to:
Owners of the Company	5,231,738	4,350,901	1,721,356	1,364,518
Non-controlling interest	29,269	23,826	4,640	2,040
	5,261,007	4,374,727	1,725,996	1,366,558
Other comprehensive income/(loss)	1	-	-	-
Total comprehensive income	5,261,008	4,374,727	1,725,996	1,366,558

Total comprehensive income attributable to:
Owners of the Company	5,231,739	4,350,901	1,721,356	1,364,518
Non-controlling interest	29,269	23,826	4,640	2,040
	5,261,008	4,374,727	1,725,996	1,366,558

Earnings per share (EPS)	11.73	9.75	3.86	3.06

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of changes in equity (Un-audited)

For the period July 2024-March 2025

Taka '000

	Share capital	Share premium	Excess of issue price over Face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2024	4,461,121	5,269,475	1,689,637	294,951	1,137,306	18,148	35,079,327	47,949,965	3,952,938	51,902,903
Total comprehensive income:
Profit/(loss) for the period	-	-	-	-	-	-	5,231,738	5,231,738	29,269	5,261,007
Other comprehensive income/(loss)	-	-	-	-	-	1	-	1	-	1
Transactions with the shareholders:
Cash dividend	-	-	-	-	-	-	(1,784,448)	(1,784,448)	(33,687)	(1,818,135)
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(3,325)	-	3,325	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	748	-	-	748	-	748
Balance as on March 31, 2025	4,461,121	5,269,475	1,689,637	294,951	1,134,729	18,149	38,529,942	51,398,004	3,948,520	55,346,524
Net asset value (NAV) per share							Tk.	115.21

For the period July 2023-March 2024

	Share capital	Share premium	Excess of issue price over Face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the company	Non-controlling interest	Total equity
Balance as on July 01, 2023	4,461,121	5,269,475	1,689,637	294,951	1,141,178	18,148	30,806,194	43,680,704	3,938,962	47,619,666
Total comprehensive income:
Profit/(loss) for the period	-	-	-	-	-	-	4,350,901	4,350,901	23,826	4,374,727
Transactions with the shareholders:
Cash dividend	-	-	-	-	-	-	(1,561,392)	(1,561,392)	(23,267)	(1,584,659)
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(3,747)	-	3,747	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	843	-	-	843	-	843
Balance as on March 31, 2024	4,461,121	5,269,475	1,689,637	294,951	1,138,274	18,148	33,599,450	46,471,056	3,939,521	50,410,577
Net asset value (NAV) per share							Tk.	104.17

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of cash flows (Un-audited)

For the period July 2024-March 2025

	July 2024 - March 2025	Taka '000 July 2023 - March 2024
Cash flows from operating activities

Cash receipts from customers and others	36,394,207	33,160,408
Cash paid to suppliers and employees	(30,100,181)	(24,573,460)
Cash generated from operations	6,294,026	8,586,948

Interest paid	(769,431)	(853,639)
Interest received	18,479	2,626
Income tax paid	(1,322,242)	(1,137,217)
Net cash generated from operating activities	4,220,832	6,598,718

Cash flows from investing activities
Acquisition of property, plant and equipment	(2,220,342)	(1,372,788)
Intangible assets	(164,411)	(205,266)
Disposal of property, plant and equipment	40,123	25,252
Dividend received	975	1,143
Short term investment	(700,000)	(200,000)
Net cash used in investing activities	(3,043,655)	(1,751,659)

Cash flows from financing activities

Net increase/(decrease) in long term borrowings	47,161	(910,718)
Net increase/(decrease) in short term borrowings	1,390,117	(2,351,356)
Dividend paid	(1,593,640)	(1,568,205)
Net cash from/(used in) financing activities	(156,362)	(4,830,279)
Increase/(decrease) in cash and cash equivalents	1,020,815	16,780
Opening cash and cash equivalents	854,106	1,135,686
Effect of exchange rate changes on cash and cash equivalents	8,179	7,958
Closing cash and cash equivalents	1,883,100	1,160,424

Net operating cash flows per share	9.46	14.79

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

QRTSEIFMDEMSEEM

Date	24 Jun 2026
Time	07:01:00
Category	Results
ID	4581J

Date	24 Jun 2026
Time	07:01:00
Category	Results
ID	4581J

t

Company Information

AI Summary

RNS Metadata

Company Information

AI Summary

RNS Metadata

Q3 Financial Results 2024-25